Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Kallyope Announces License Agreement with Novo Nordisk
Details : Under the terms of the license agreement, Novo Nordisk will discover novel peptide therapeutics including as a potential new mechanism for the treatment of obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 09, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : K-757,K-833
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : K-757 and K-833 are new oral nutrient receptor agonists that enhance the body’s natural metabolic signals to stimulate the secretion of multiple appetite-suppressing satiety hormones, including GLP-1, and several other well validated satiety hormones, ...
Product Name : K-757
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 27, 2023
Lead Product(s) : K-757,K-833
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Sosei Group Corporation
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The agreement will leverage Sosei Heptares’ GPCR Diversified Compound Library and GPCR expertise with the innovative Kallyope gut-brain axis platform, which combines single-cell sequencing, circuit mapping, computational biology and enteroid phenotypic...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 17, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Sosei Group Corporation
Deal Size : Undisclosed
Deal Type : Collaboration